CN111741960A - 一种3,4-二氢噻吩并[3,2-d]嘧啶类化合物的晶型及其制备方法 - Google Patents

一种3,4-二氢噻吩并[3,2-d]嘧啶类化合物的晶型及其制备方法 Download PDF

Info

Publication number
CN111741960A
CN111741960A CN201980012560.XA CN201980012560A CN111741960A CN 111741960 A CN111741960 A CN 111741960A CN 201980012560 A CN201980012560 A CN 201980012560A CN 111741960 A CN111741960 A CN 111741960A
Authority
CN
China
Prior art keywords
compound
degrees
preparation
water
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980012560.XA
Other languages
English (en)
Other versions
CN111741960B (zh
Inventor
熊剑
王晶晶
胡伯羽
谭海忠
陈新海
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huinuo Biomedical Technology Hangzhou Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN111741960A publication Critical patent/CN111741960A/zh
Application granted granted Critical
Publication of CN111741960B publication Critical patent/CN111741960B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

3,4‑二氢噻吩并[3,2‑d]嘧啶类化合物(1)的A晶型及其制备方法和在制备抗HCMV病毒药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201980012560.XA 2018-02-08 2019-01-29 一种3,4-二氢噻吩并[3,2-d]嘧啶类化合物的晶型及其制备方法 Active CN111741960B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018101306258 2018-02-08
CN201810130625 2018-02-08
PCT/CN2019/073700 WO2019154192A1 (zh) 2018-02-08 2019-01-29 一种3,4-二氢噻吩并[3,2-d]嘧啶类化合物的晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN111741960A true CN111741960A (zh) 2020-10-02
CN111741960B CN111741960B (zh) 2021-06-25

Family

ID=67549284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980012560.XA Active CN111741960B (zh) 2018-02-08 2019-01-29 一种3,4-二氢噻吩并[3,2-d]嘧啶类化合物的晶型及其制备方法

Country Status (7)

Country Link
US (1) US11174270B2 (zh)
EP (1) EP3753942B1 (zh)
JP (1) JP7076845B2 (zh)
KR (1) KR102423393B1 (zh)
CN (1) CN111741960B (zh)
AU (1) AU2019218150B2 (zh)
WO (1) WO2019154192A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784390A (zh) * 2003-05-02 2006-06-07 拜耳医药保健股份公司 具有抗病毒性能的取代二氢喹唑啉
CN1980925A (zh) * 2004-05-07 2007-06-13 艾库里斯有限及两合公司 具有抗病毒活性的取代的氮杂喹唑啉
WO2016109360A1 (en) * 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Dihydroquinazoline inhibitors of viral terminase
WO2018028556A1 (zh) * 2016-08-08 2018-02-15 南京明德新药研发股份有限公司 抗hcmv病毒化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784390A (zh) * 2003-05-02 2006-06-07 拜耳医药保健股份公司 具有抗病毒性能的取代二氢喹唑啉
CN1980925A (zh) * 2004-05-07 2007-06-13 艾库里斯有限及两合公司 具有抗病毒活性的取代的氮杂喹唑啉
WO2016109360A1 (en) * 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Dihydroquinazoline inhibitors of viral terminase
WO2018028556A1 (zh) * 2016-08-08 2018-02-15 南京明德新药研发股份有限公司 抗hcmv病毒化合物

Also Published As

Publication number Publication date
EP3753942B1 (en) 2024-01-03
KR102423393B1 (ko) 2022-07-21
US20210024538A1 (en) 2021-01-28
WO2019154192A1 (zh) 2019-08-15
EP3753942A1 (en) 2020-12-23
KR20200118161A (ko) 2020-10-14
AU2019218150B2 (en) 2021-05-13
EP3753942A4 (en) 2021-10-27
US11174270B2 (en) 2021-11-16
AU2019218150A1 (en) 2020-09-17
JP2021512928A (ja) 2021-05-20
CN111741960B (zh) 2021-06-25
JP7076845B2 (ja) 2022-05-30

Similar Documents

Publication Publication Date Title
US20200330472A1 (en) Method of treating cancer
EP3070089B1 (en) Aminomethyl tryptanthrin derivative, preparation method and application thereof
JP5524343B2 (ja) ベンゾジアゼピンブロモドメイン阻害剤
EP3206688A1 (en) Method for treating cancer
WO2021023194A1 (zh) 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法
CN113880772B (zh) 一类cdk激酶抑制剂及其应用
WO2021023195A1 (zh) 吡嗪-2（1h）-酮类化合物的d晶型及其制备方法
KR20230048106A (ko) 스플라이싱을 조절하는 조성물
CN111741960B (zh) 一种3,4-二氢噻吩并[3,2-d]嘧啶类化合物的晶型及其制备方法
WO2020164603A1 (zh) 固体形式的fgfr抑制剂化合物及其制备方法
CN113646312B (zh) 固体形式的brd4抑制剂化合物及其制备方法与应用
CN110590681B (zh) 一种新型喹唑啉酮类化合物及其制备方法和应用
CN110759891B (zh) Set8赖氨酸甲基转移酶抑制剂及其中间体、制备方法和用途
WO2020147838A1 (zh) 一种egfr抑制剂的盐、晶型及其制备方法
WO2019101058A1 (zh) 一种urat1抑制剂的晶型及其制备方法
CN111018839A (zh) 三氮唑醇类衍生物及其制备方法和应用
WO2017152858A1 (zh) 色瑞替尼的晶型及其制备方法
CN114805350B (zh) 一类苯并杂环-吡啶酮衍生物及其制备方法和用途
EP3819297B1 (en) Crystal forms of thiazole compound and application thereof
RU2794977C2 (ru) Соль ингибитора lsd1 и её полиморфная форма
CN113784968A (zh) Wee1抑制剂化合物的晶型及其应用
CN106432244B (zh) 一种hedgehog信号通路抑制剂的结晶形式及其制备方法
CN116120301A (zh) 一种化合物的甲磺酸盐晶型、药物组合物及用途
CN118027024A (zh) 吡啶并[1,2-a]嘧啶-4-酮衍生物及其制备方法和用途
CN115710257A (zh) 一种酰胺化合物的硫酸盐晶型、药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40038947

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20211110

Address after: 310018 room 1-404, Heda Medicine Valley Center, No. 291, Fucheng Road, Xiasha street, Hangzhou Economic and Technological Development Zone, Hangzhou, Zhejiang Province

Patentee after: Huinuo biomedical technology (Hangzhou) Co.,Ltd.

Address before: 210032 room 218, business office building, No. 9, Gaoxin Road, Jiangbei new district, Nanjing, Jiangsu Province

Patentee before: Nanjing Mingde New Drug Development Co.,Ltd.

TR01 Transfer of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Crystal form and preparation method of a 3,4-dihydrothieno [3,2-d] pyrimidine compound

Granted publication date: 20210625

Pledgee: Hangzhou United Rural Commercial Bank Co.,Ltd. Xiasha sub branch

Pledgor: Huinuo biomedical technology (Hangzhou) Co.,Ltd.

Registration number: Y2024980014739

PE01 Entry into force of the registration of the contract for pledge of patent right